Landscape Capital Management L.L.C. Acquires 7,693 Shares of ResMed Inc. (NYSE:RMD)

Landscape Capital Management L.L.C. lifted its position in ResMed Inc. (NYSE:RMD) by 59.6% in the 4th quarter, Holdings Channel.com reports. The fund owned 20,609 shares of the medical equipment provider’s stock after acquiring an additional 7,693 shares during the period. ResMed comprises 0.5% of Landscape Capital Management L.L.C.’s investment portfolio, making the stock its 29th largest holding. Landscape Capital Management L.L.C.’s holdings in ResMed were worth $4,713,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of RMD. Howard Capital Management Inc. grew its stake in ResMed by 5.3% in the 4th quarter. Howard Capital Management Inc. now owns 900 shares of the medical equipment provider’s stock worth $206,000 after acquiring an additional 45 shares in the last quarter. SkyView Investment Advisors LLC increased its stake in ResMed by 2.0% during the 3rd quarter. SkyView Investment Advisors LLC now owns 2,610 shares of the medical equipment provider’s stock valued at $637,000 after purchasing an additional 51 shares in the last quarter. Wedmont Private Capital raised its stake in ResMed by 2.6% in the 4th quarter. Wedmont Private Capital now owns 2,032 shares of the medical equipment provider’s stock worth $475,000 after acquiring an additional 52 shares during the last quarter. HighPoint Advisor Group LLC raised its stake in shares of ResMed by 2.6% in the fourth quarter. HighPoint Advisor Group LLC now owns 2,570 shares of the medical equipment provider’s stock worth $610,000 after purchasing an additional 64 shares during the last quarter. Finally, Brooklyn Investment Group raised its position in ResMed by 8.1% during the 4th quarter. Brooklyn Investment Group now owns 911 shares of the medical equipment provider’s stock worth $208,000 after buying an additional 68 shares during the last quarter. Institutional investors own 54.98% of the company’s stock.

Insider Buying and Selling at ResMed

In other news, insider Kaushik Ghoshal sold 9,745 shares of the business’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $239.31, for a total value of $2,332,075.95. Following the completion of the sale, the insider now directly owns 9,725 shares of the company’s stock, valued at approximately $2,327,289.75. The trade was a 50.05 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Peter C. Farrell sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $242.11, for a total value of $484,220.00. Following the completion of the sale, the director now owns 77,218 shares of the company’s stock, valued at approximately $18,695,249.98. This represents a 2.52 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 39,004 shares of company stock valued at $9,178,648. Insiders own 0.71% of the company’s stock.

ResMed Trading Down 4.4 %

RMD opened at $213.11 on Friday. ResMed Inc. has a 52 week low of $172.19 and a 52 week high of $263.05. The company has a quick ratio of 2.29, a current ratio of 3.33 and a debt-to-equity ratio of 0.13. The business has a fifty day simple moving average of $231.65 and a 200-day simple moving average of $237.37. The firm has a market cap of $31.30 billion, a P/E ratio of 25.16, a P/E/G ratio of 1.53 and a beta of 0.74.

ResMed (NYSE:RMD) last announced its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share for the quarter, beating analysts’ consensus estimates of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%. On average, equities analysts expect that ResMed Inc. will post 9.47 earnings per share for the current year.

ResMed Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 13th were paid a dividend of $0.53 per share. The ex-dividend date was Thursday, February 13th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.99%. ResMed’s payout ratio is 25.03%.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on RMD. Morgan Stanley initiated coverage on ResMed in a report on Wednesday, March 19th. They issued an “overweight” rating and a $280.00 price objective for the company. Citigroup raised shares of ResMed from a “neutral” rating to a “buy” rating in a report on Wednesday, March 5th. StockNews.com lowered ResMed from a “buy” rating to a “hold” rating in a research note on Wednesday. Stifel Nicolaus lowered their price target on shares of ResMed from $250.00 to $240.00 and set a “hold” rating on the stock in a research report on Wednesday, March 5th. Finally, JPMorgan Chase & Co. upped their target price on ResMed from $270.00 to $286.00 and gave the company an “overweight” rating in a report on Friday, January 31st. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, ResMed presently has a consensus rating of “Moderate Buy” and an average target price of $249.73.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.